Literature DB >> 23064360

TNF signaling drives myeloid-derived suppressor cell accumulation.

Xueqiang Zhao1, Lijie Rong, Xiaopu Zhao, Xiao Li, Xiaoman Liu, Jingjing Deng, Hao Wu, Xia Xu, Ulrike Erben, Peihua Wu, Uta Syrbe, Joachim Sieper, Zhihai Qin.   

Abstract

TNF, an inflammatory cytokine that is enriched in the tumor microenvironment, promotes tumor growth and subverts innate immune responses to cancer cells. We previously reported that tumors implanted in TNF receptor-deficient (Tnfr-/-) mice are spontaneously rejected; however, the molecular mechanisms underlying this rejection are unclear. Here we report that TNF signaling drives the peripheral accumulation of myeloid-derived suppressor cells (MDSCs). MDSCs expand extensively during inflammation and tumor progression in mice and humans and can enhance tumor growth by repressing T cell-mediated antitumor responses. Peripheral accumulation of MDSCs was drastically impaired in Tnfr-/- mice. Signaling of TNFR-2, but not TNFR-1, promoted MDSC survival through upregulation of cellular FLICE-inhibitory protein (c-FLIP) and inhibition of caspase-8 activity. Loss of TNFRs impaired the induction of MDSCs from bone marrow cells, but this could be reversed by treatment with caspase inhibitors. These results demonstrate that TNFR-2 signaling promotes MDSC survival and accumulation and helps tumor cells evade the immune system.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23064360      PMCID: PMC3484453          DOI: 10.1172/JCI64115

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  57 in total

Review 1.  The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4(+) FoxP3(+) regulatory T cells.

Authors:  Xin Chen; Joost J Oppenheim
Journal:  Immunology       Date:  2011-06-02       Impact factor: 7.397

2.  Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression.

Authors:  Felix Roth; Adriana C De La Fuente; Jennifer L Vella; Alessia Zoso; Luca Inverardi; Paolo Serafini
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

Review 3.  Anti-TNF therapy: safety aspects of taking the risk.

Authors:  Hemda Rosenblum; Howard Amital
Journal:  Autoimmun Rev       Date:  2011-05-05       Impact factor: 9.754

4.  Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells.

Authors:  Hidekazu Kitakata; Yoko Nemoto-Sasaki; Yutaka Takahashi; Toshikazu Kondo; Masayoshi Mai; Naofumi Mukaida
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

5.  Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL.

Authors:  Pratima Sinha; Olesya Chornoguz; Virginia K Clements; Konstantin A Artemenko; Roman A Zubarev; Suzanne Ostrand-Rosenberg
Journal:  Blood       Date:  2011-03-30       Impact factor: 22.113

6.  CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

Authors:  Z Qin; T Blankenstein
Journal:  Immunity       Date:  2000-06       Impact factor: 31.745

Review 7.  TNF-R1 signaling: a beautiful pathway.

Authors:  Guoqing Chen; David V Goeddel
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

Review 8.  Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function.

Authors:  Thomas Condamine; Dmitry I Gabrilovich
Journal:  Trends Immunol       Date:  2010-11-08       Impact factor: 16.687

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

10.  Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction.

Authors:  Zhihai Qin; Hye-Jung Kim; Jens Hemme; Thomas Blankenstein
Journal:  J Exp Med       Date:  2002-06-03       Impact factor: 14.307

View more
  156 in total

1.  Autocrine IL6-Mediated Activation of the STAT3-DNMT Axis Silences the TNFα-RIP1 Necroptosis Pathway to Sustain Survival and Accumulation of Myeloid-Derived Suppressor Cells.

Authors:  Alyssa D Smith; Chunwan Lu; Daniela Payne; Amy V Paschall; John D Klement; Priscilla S Redd; Mohammed L Ibrahim; Dafeng Yang; Qimei Han; Zhuoqi Liu; Huidong Shi; Thomas J Hartney; Asha Nayak-Kapoor; Kebin Liu
Journal:  Cancer Res       Date:  2020-06-17       Impact factor: 12.701

2.  Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer.

Authors:  Roy Xiao; Clint T Allen; Linda Tran; Priya Patel; So-Jin Park; Zhong Chen; Carter Van Waes; Nicole C Schmitt
Journal:  Oncoimmunology       Date:  2018-08-01       Impact factor: 8.110

Review 3.  Role of myeloid-derived suppressor cells in allogeneic hematopoietic cell transplantation.

Authors:  Brent H Koehn; Bruce R Blazar
Journal:  J Leukoc Biol       Date:  2017-02-01       Impact factor: 4.962

4.  γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer.

Authors:  Pin Wu; Dang Wu; Chao Ni; Jun Ye; Wuzhen Chen; Guoming Hu; Zhen Wang; Changrong Wang; Zhigang Zhang; Wenjie Xia; Zhigang Chen; Ke Wang; Tao Zhang; Jinghong Xu; Yuehua Han; Ting Zhang; Xianguo Wu; Jianwei Wang; Weihua Gong; Shu Zheng; Fuming Qiu; Jun Yan; Jian Huang
Journal:  Immunity       Date:  2014-05-08       Impact factor: 31.745

5.  Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis.

Authors:  Jeremy D Waight; Colleen Netherby; Mary L Hensen; Austin Miller; Qiang Hu; Song Liu; Paul N Bogner; Matthew R Farren; Kelvin P Lee; Kebin Liu; Scott I Abrams
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

6.  Hypoxia-inducible factors: a central link between inflammation and cancer.

Authors:  Daniel Triner; Yatrik M Shah
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

7.  Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression.

Authors:  R J Seager; Cynthia Hajal; Fabian Spill; Roger D Kamm; Muhammad H Zaman
Journal:  Converg Sci Phys Oncol       Date:  2017-07-28

8.  Anti-Jagged Immunotherapy Inhibits MDSCs and Overcomes Tumor-Induced Tolerance.

Authors:  Rosa A Sierra; Jimena Trillo-Tinoco; Eslam Mohamed; Lolie Yu; Bhagelu R Achyut; Ali Arbab; Jennifer W Bradford; Barbara A Osborne; Lucio Miele; Paulo C Rodriguez
Journal:  Cancer Res       Date:  2017-09-13       Impact factor: 12.701

9.  Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist.

Authors:  Susumu Fujiwara; Hiroshi Nagai; Noriko Shimoura; Shuntaro Oniki; Takayuki Yoshimoto; Chikako Nishigori
Journal:  J Invest Dermatol       Date:  2014-01-27       Impact factor: 8.551

10.  CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

Authors:  Michelle K Gleason; Julie A Ross; Erica D Warlick; Troy C Lund; Michael R Verneris; Andres Wiernik; Stephen Spellman; Michael D Haagenson; Alexander J Lenvik; Mark R Litzow; Pearlie K Epling-Burnette; Bruce R Blazar; Louis M Weiner; Daniel J Weisdorf; Daniel A Vallera; Jeffrey S Miller
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.